MSI (Microsatellite instability)

P2, N=50, Not yet recruiting, Fred Hutchinson Cancer Center

P1, N=18, Recruiting, Thomas Jefferson University | Not yet recruiting --> Recruiting | Trial completion date: Jan 2027 --> Apr 2028 | Trial primary completion date: Jan 2027 --> Oct 2027

The revised tumor burden score (rTBS) provides a clinically actionable, cost-effective tool to enhance prognostic stratification in patients with metastatic colorectal cancer (mCRC) receiving immunotherapy. By integrating routinely available metrics (CEA, metastatic organ count, and target lesions), rTBS achieves superior prognostic discrimination (AUC = 0.768) compared to traditional biomarkers such as TMB (AUC = 0.656) and consistently stratifies outcomes across molecular subtypes. Of particular clinical relevance, rTBS identifies patients with more favorable prognosis within the MSI-L/MSS/TMB-Low subgroup, addressing a major unmet need in this biomarker-limited population. It also refines risk stratification in MSI-H/TMB-High patients by identifying those with high tumor burden and poor prognosis. By leveraging readily accessible clinical and imaging data, rTBS circumvents the need for costly molecular profiling, bringing pragmatic risk stratification within reach even in resource-constrained settings. These findings position rTBS as a useful decision-support tool for prognostic evaluation, assisting clinicians in personalizing management strategies for mCRC.

This study reveals aberrant TRIP13 expression across multiple cancers and its association with immune modulation and tumor aggressiveness. The elevation of TRIP13 in palbociclib resistant prostate cancer, together with the regulatory E2F1-TRIP13-HECTD3 axis, highlights its potential as a prognostic biomarker and therapeutic target.

Neoadjuvant chemotherapy with docetaxel plus S-1 regimen was administered, resulting in stable disease(SD)...The patient continued adjuvant nivolumab therapy postoperatively and remained disease-free. This case highlights the potential role of perioperative immunotherapy with nivolumab in MSI-H EGJ cancers and the promise of personalized treatment strategies.

Importantly, the therapeutic potential of targeting USP21 to enhance anti-PD-1 efficacy was further validated in huCD34+ humanized mice. Collectively, our findings identify USP21 as a pivotal regulator of immune evasion, and inhibiting USP21 represents a promising adjuvant strategy to increase the efficacy of ICB in CRC.

P2, N=44, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: May 2028 --> May 2030 | Trial primary completion date: May 2028 --> May 2030

Given her advanced age and frailty, she was treated with a first-line combination of pembrolizumab, dabrafenib, and trametinib. She achieved a radiographic complete response (CR) and has remained progression-free for over 26 months. This case highlights the potential synergy between MAPK pathway inhibition and immunotherapy, suggesting that even short-course targeted therapy may favorably remodel the tumor microenvironment to enable durable disease control in high-risk MSI-H/BRAF-mutant mCRC.

Integrated genomic and transcriptomic profiling refines prognostic stratification in cholangiocarcinoma independent of therapeutic actionability. KRAS-TP53 co-mutation and the Mesenchymal transcriptomic subtype represent independent high-risk markers detectable on routine FFPE tissue. These features complement actionable alterations and may inform patient selection and clinical trial design.

The nomogram model, which combines clinicopathological features with pre-treatment CT-based radiomics features, demonstrates greater predictive accuracy for dMMR/MSI colon cancer than the standalone clinical and radiomics models.

Neoadjuvant immunotherapy is safe and effective for resectable LACRC. Neoadjuvant immunotherapy alone for resectable MSI-H colorectal cancer (CRC) can achieve satisfactory results, and neoadjuvant immunotherapy in combination with various forms of conventional therapy for patients with resectable MSS CRC could also achieve better short-term effects.

P1, N=68, Terminated, Seagen, a wholly owned subsidiary of Pfizer | Trial completion date: Aug 2026 --> Apr 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Aug 2026 --> Apr 2026; The trial was terminated for strategic reasons. The decision was not based on any safety concerns